The current stock price of SXTP is 4.31 USD. In the past month the price increased by 139.32%. In the past year, price decreased by -66.68%.
ChartMill assigns a technical rating of 4 / 10 to SXTP. When comparing the yearly performance of all stocks, SXTP is a bad performer in the overall market: 91.99% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to SXTP. SXTP may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months SXTP reported a non-GAAP Earnings per Share(EPS) of -23.4. The EPS increased by 48.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -126.7% | ||
| ROE | -191.31% | ||
| Debt/Equity | 0.03 |
For the next year, analysts expect an EPS growth of 91.22% and a revenue growth 164.27% for SXTP
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
60 DEGREES PHARMA INC
1025 Connecticut Avenue Nw, Suite 1000
WASHINGTON WASHINGTON DC US
Employees: 3
Phone: 12023275422
60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
The current stock price of SXTP is 4.31 USD. The price decreased by -10.95% in the last trading session.
SXTP does not pay a dividend.
SXTP has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
The Revenue of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 164.27% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
You can find the ownership structure of 60 DEGREES PHARMA INC (SXTP) on the Ownership tab.